G
Graziella Pinotti
Researcher at Ospedale di Circolo e Fondazione Macchi
Publications - 140
Citations - 6368
Graziella Pinotti is an academic researcher from Ospedale di Circolo e Fondazione Macchi. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 33, co-authored 140 publications receiving 5382 citations. Previous affiliations of Graziella Pinotti include Catholic University of the Sacred Heart & University of Insubria.
Papers
More filters
Journal ArticleDOI
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani,Meredith M. Regan,Barbara Walley,Gini F. Fleming,Marco Colleoni,István Láng,Henry L. Gomez,Carlo Tondini,Harold J. Burstein,Edith A. Perez,Eva Ciruelos,Vered Stearns,Hervé Bonnefoi,Silvana Martino,Charles E. Geyer,Graziella Pinotti,Fabio Puglisi,Diana Crivellari,Thomas Ruhstaller,Eric P. Winer,Manuela Rabaglio-Poretti,Rudolf Maibach,Barbara Ruepp,Anita Giobbie-Hurder,Karen N. Price,Jürg Bernhard,Weixiu Luo,Karin Ribi,Giuseppe Viale,Alan S. Coates,Richard D. Gelber,Aron Goldhirsch,Prudence A. Francis +32 more
TL;DR: In premenopausal women with hormone-receptor-positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppressed, significantly reduced recurrence.
Journal ArticleDOI
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Andrés J.M. Ferreri,Michele Reni,Marco Foppoli,Maurizio Martelli,Gerasimus A. Pangalis,Maurizio Frezzato,Maria Giuseppina Cabras,Alberto Fabbri,Gaetano Corazzelli,Fiorella Ilariucci,Giuseppe Rossi,Riccardo Soffietti,Caterina Stelitano,Daniele Vallisa,Francesco Zaja,Lucia Zoppegno,Gian Marco Aondio,Giuseppe Avvisati,Monica Balzarotti,Alba A. Brandes,José Luis Crespo Fajardo,Henry L. Gomez,Attilio Guarini,Graziella Pinotti,Luigi Rigacci,Catrina Uhlmann,Piero Picozzi,Paolo Vezzulli,Maurilio Ponzoni,Emanuele Zucca,Federico Caligaris-Cappio,Franco Cavalli +31 more
TL;DR: In patients aged 75 years and younger with primary CNS lymphoma, the addition of high-dose cytarabine to high- dose methotrexate provides improved outcome with acceptable toxicity compared with high- doses of metotrexate alone.
Journal ArticleDOI
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
Emanuele Zucca,Annarita Conconi,Ennio Pedrinis,Sergio Cortelazzo,Teresio Motta,Mary Gospodarowicz,B. Patterson,Andrés J.M. Ferreri,Maurilio Ponzoni,Liliana Devizzi,Roberto Giardini,Graziella Pinotti,Carlo Capella,Pier Luigi Zinzani,Stefano Pileri,Armando López-Guillermo,Elias Campo,Achille Ambrosetti,Luca Baldini,Franco Cavalli +19 more
TL;DR: The data confirm the indolent nature of nongastric MALT lymphomas and the high rate of patients presenting with disseminated disease, which, when limited to mucosal sites, was not associated with a poorer outcome.
Journal ArticleDOI
Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue
Enrico Roggero,Emanuele Zucca,Graziella Pinotti,Anna Pascarella,Carlo Capella,Antonella Savio,Ennio Pedrinis,Alessandro Paterlini,Achille Venco,Franco Cavalli +9 more
TL;DR: The effects of antibiotic therapy for H. pylori infection in 26 patients with low-grade gastric MALT lymphoma, an uncommon tumor with an indolent natural history and prolonged confinement to the site of origin, showed no change in the condition of the patients after treatment.
Journal ArticleDOI
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A. Francis,Prudence A. Francis,Olivia Pagani,Gini F. Fleming,Barbara Walley,M.A. Colleoni,István Láng,Henry L. Gomez,Carlo Tondini,Eva Ciruelos,Harold J. Burstein,H. Bonnefoi,Meritxell Bellet,Silvana Martino,Charles E. Geyer,Matthew P. Goetz,Vered Stearns,Graziella Pinotti,Fabio Puglisi,S. Spazzapan,Miguel Angel Climent,Lorenzo Pavesi,Thomas Ruhstaller,Nancy E. Davidson,Robert E. Coleman,Marc Debled,Stefan Buchholz,JN Ingle,Eric P. Winer,Rudolf Maibach,Manuela Rabaglio-Poretti,Barbara Ruepp,A. Di Leo,Alan S. Coates,Richard D. Gelber,A. Goldhirsch,Meredith M. Regan +36 more
TL;DR: Among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8‐year rates of both disease‐free and overall survival than tamox ifen alone and the use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence.